The Voyager Therapeutics Inc. (VYGR) Upgraded by Zacks Investment Research to “Buy”

The Voyager Therapeutics Inc. (VYGR) Upgraded by Zacks Investment Research to “Buy”

Zacks Investment Research upgraded shares of Voyager Therapeutics Inc. (NASDAQ:VYGR) from a hold rating to a buy rating in a research note issued to investors on Wednesday morning. They currently have $13.00 target price on the stock.

According to Zacks, “Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson’s disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington’s disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

VYGR has been the topic of several other reports. Wedbush reissued an outperform rating and issued a $36.00 target price on shares of Voyager Therapeutics in a research report on Wednesday, June 22nd. Stifel Nicolaus assumed coverage on Voyager Therapeutics in a research report on Thursday, July 14th. They set a buy rating and a $33.00 price target on the stock. Piper Jaffray Cos. set a $37.00 price target on Voyager Therapeutics and gave the stock a buy rating in a research report on Thursday, August 11th. Finally, Cowen and Company reaffirmed a buy rating on shares of Voyager Therapeutics in a research report on Wednesday, June 22nd. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Voyager Therapeutics presently has a consensus rating of Buy and an average price target of $26.80.

Shares of Voyager Therapeutics (NASDAQ:VYGR) traded down 0.62% during midday trading on Wednesday, hitting $11.20. The stock had a trading volume of 1,721 shares. The stock’s market cap is $299.35 million. The firm has a 50 day moving average price of $12.79 and a 200-day moving average price of $12.71. Voyager Therapeutics has a 52-week low of $8.12 and a 52-week high of $30.54.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Thursday, August 11th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.03. Voyager Therapeutics had a negative net margin of 150.47% and a negative return on equity of 25.13%. Equities analysts predict that Voyager Therapeutics will post ($1.53) EPS for the current fiscal year.

Several large investors have recently bought and sold shares of the company. Strs Ohio raised its stake in Voyager Therapeutics by 531.6% in the second quarter. Strs Ohio now owns 12,000 shares of the company’s stock valued at $131,000 after buying an additional 10,100 shares during the last quarter. BlackRock Group LTD purchased a new stake in Voyager Therapeutics during the second quarter valued at about $158,000. Teachers Advisors Inc. raised its stake in Voyager Therapeutics by 220.0% in the second quarter. Teachers Advisors Inc. now owns 18,757 shares of the company’s stock valued at $206,000 after buying an additional 12,895 shares during the last quarter. California State Teachers Retirement System raised its stake in Voyager Therapeutics by 97.1% in the second quarter. California State Teachers Retirement System now owns 24,611 shares of the company’s stock valued at $270,000 after buying an additional 12,123 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. raised its stake in Voyager Therapeutics by 52.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 26,281 shares of the company’s stock valued at $289,000 after buying an additional 9,010 shares during the last quarter. 39.66% of the stock is currently owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company is focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain.

Related posts

Leave a Comment